Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Eligibility and implementation of disease-modifying therapy for primary progressive multiple sclerosis in a UK cohort

Tallantyre, Emma ORCID:, Castle, Daniel, Karamura, Paul, Brice, Thomas, Joseph, Fady, Harding, Katharine and Robertson, Neil ORCID: 2020. Eligibility and implementation of disease-modifying therapy for primary progressive multiple sclerosis in a UK cohort. Multiple Sclerosis and Related Disorders 42 , 102056. 10.1016/j.msard.2020.102056

[thumbnail of MSARD_Tallantyre_clean.pdf] PDF - Accepted Post-Print Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (332kB)


Background: As disease-modifying therapies become approved for primary progressive multiple sclerosis (PPMS), services must be aligned in readiness. Methods: In this paper we use population and clinic-based data to estimate eligibility rates for ocrelizumab, and the extent of additional service requirements necessary to ensure its widespread introduction in PPMS. Results: Overall population estimates for the incidence and prevalence of people with PPMS who are eligible for ocrelizumab are 1.6 and 4.2 per 100,000 respectively. The majority (87%) of incident cases of PPMS satisfied clinical eligibility criteria for ocrelizumab but lacked radiological evidence of disease activity due to a historical tendency not to routinely monitor using MRI in this group. The majority of prevalent patients did not satisfy clinical eligibility criteria for ocrelizumab, mainly because of advanced disease duration or disability. Conclusions: These findings illustrate the fact that there has been a tendency for people with PPMS not to receive routine clinical and radiological monitoring. Additional planning or resources will be required to facilitate contemporary disease re-evaluation and surveillance at a population level.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG)
Publisher: Elsevier
ISSN: 2211-0348
Date of First Compliant Deposit: 24 March 2020
Date of Acceptance: 13 March 2020
Last Modified: 07 Nov 2023 16:38

Actions (repository staff only)

Edit Item Edit Item


Downloads per month over past year

View more statistics